prikaz prve stranice dokumenta Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
  Download
PDF 1.9 MB
Scientific paper - Original scientific paper
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
Haematologica, 102 (2017), 8; 1361-1367. https://doi.org/10.3324/haematol.2017.167080
Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Tobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore More authors...

Cite this document

Gullaksen, S. E., Skavland, J., Gavasso, S., Tosevski, V., Warzocha, K., Dumrese, C. ... Gjertsen, B. T. (2017). Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica, 102. (8), 1361-1367. doi: 10.3324/haematol.2017.167080

Gullaksen, Stein Erik, et al. "Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib." Haematologica, vol. 102, no. 8, 2017, pp. 1361-1367. https://doi.org/10.3324/haematol.2017.167080

Gullaksen, Stein Erik, Jørn Skavland, Sonia Gavasso, Vinko Tosevski, Krzysztof Warzocha, Claudia Dumrese, Augustin Ferrant, et al. "Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib." Haematologica 102, no. 8 (2017): 1361-1367. https://doi.org/10.3324/haematol.2017.167080

Gullaksen, S. E., et al. (2017) 'Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib', Haematologica, 102(8), pp. 1361-1367. doi: 10.3324/haematol.2017.167080

Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, and sur.. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica [Internet]. 2017 August [cited 2025 February 11];102(8):1361-1367. doi: 10.3324/haematol.2017.167080

S. E. Gullaksen, et al., "Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib", Haematologica, vol. 102, no. 8, pp. 1361-1367, August 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:821605. [Accessed: 11 February 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
AuthorStein-Erik Gullaksen
AuthorJørn Skavland
AuthorSonia Gavasso
AuthorVinko Tosevski
AuthorKrzysztof Warzocha
AuthorClaudia Dumrese
AuthorAugustin Ferrant
AuthorTobias Gedde-Dahl
AuthorAndrzej Hellmann
AuthorJeroen Janssen
AuthorBoris Labar
AuthorAlois Lang
AuthorWaleed Majeed
AuthorGeorgi Mihaylov
AuthorJesper Stentoft
AuthorLeif Stenke
AuthorJosef Thaler
AuthorNoortje Thielen
AuthorGregor Verhoef
AuthorJaroslava Voglova
AuthorGert Ossenkoppele
AuthorAndreas Hochhaus
AuthorHenrik Hjorth-Hansen
AuthorSatu Mustjoki
AuthorSieghart Sopper
AuthorFrancis Giles
AuthorKimmo Porkka
AuthorDominik Wolf
AuthorBjørn Tore Gjertsen
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Monitoring of single cell signal transduction in leukemic cellular subsets has been proposed to provide deeper understanding of disease biology and prognosis, but has so far not been tested in a clinical trial of targeted therapy. We developed a complete mass cytometry analysis pipeline for characterization of intracellular signal transduction patterns in the major leukocyte subsets of chronic phase chronic myeloid leukemia. Changes in phosphorylated Bcr-Abl1 and the signaling pathways involved were readily identifiable in peripheral blood single cells already within three hours of the patient receiving oral nilotinib. The signal transduction profiles of healthy donors were clearly distinct from those of the patients at diagnosis. Furthermore, using principal component analysis, we could show that phosphorylated transcription factors STAT3 (Y705) and CREB (S133) within seven days reflected BCR-ABL1IS at three and six months. Analyses of peripheral blood cells longitudinally collected from patients in the ENEST1st clinical trial showed that single cell mass cytometry appears to be highly suitable for future investigations addressing tyrosine kinase inhibitor dosing and effect.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleHaematologica
Numberingvol. 102, no. 8, pp. 1361-1367
p-ISSN0390-6078
DOIhttps://doi.org/10.3324/haematol.2017.167080
URN:NBNurn:nbn:hr:105:821605
Publication2017-08
Document URLhttps://doi.org/10.3324/haematol.2017.167080
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:07:46